Handelsavisen
prelaunch
Companies Healthcare PLRZ.O
PL
PLRZ.O NASDAQ Biotechnology & Medical Research

Polyrizon Ltd

$10,59
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
18,9M USD
P/E
EV / Rev
Div yield
Op margin
ROE
-15,9 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
$16,13–$17,07
Prev close
$16,50
Open
$16,13
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Polyrizon Ltd is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of innovative therapies.

Business. Polyrizon Ltd (PLRZ.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Polyrizon is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-15,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PLRZ.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PLRZ.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Polyrizon Ltd (PLRZ.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Polyrizon is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Polyrizon maintains a strong liquidity position, with a current ratio of 29.03, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $1.3 million, and it has no long-term debt, contributing to a debt-to-equity ratio of 0.0. The price-to-book ratio of 1.34 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium.

    The company's profitability metrics are negative, with a return on equity of -15.89% and a return on assets of -15.56%, reflecting a loss-making position. The operating income and net income are -$6.25 million and -$3.34 million, respectively, indicating a challenging financial performance. The EV/EBITDA ratio of -4.29 further underscores the company's unprofitability and the market's cautious valuation.

    Polyrizon's revenue concentration and geographic exposure are not explicitly detailed in the available data, but the absence of disclosed segments suggests a potentially undiversified business model. The company's operations are likely concentrated in a single therapeutic area or geographic region, which could pose concentration risks.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of -$4.53 million and free cash flow of -$3.0 million indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -$7,000 is minimal, suggesting limited investment in expansion or new projects.

    Risk factors for Polyrizon include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the valuation adjustments do not indicate significant dilution pressures. However, the negative profitability metrics and cash outflows highlight operational risks that could affect long-term stability.

    Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of recent major events suggests a stable but stagnant operational environment.

    Key takeaways
    • Polyrizon has a strong liquidity position with a current ratio of 29.03 and no long-term debt.
    • The company is currently unprofitable, with a return on equity of -15.89% and a return on assets of -15.56%.
    • The EV/EBITDA ratio of -4.29 reflects the market's cautious valuation of the company's unprofitable operations.
    • The company's revenue concentration and geographic exposure are not explicitly detailed, suggesting potential diversification risks.
    • The absence of immediate liquidity or dilution flags indicates a low near-term risk of capital structure changes.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $10,59
    Market cap
    $28.1M
    Enterprise value
    $26.8M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    1.3x
    P / Tangible book
    1.3x
    Tangible book
    $21.0M
    Net cash
    $1.3M
    Current ratio
    29.0
    Debt / equity
    0.0
    ROA
    -15.6%
    ROE
    -15.9%
    Cash conversion
    136.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-15,9 %Above median
    D/E0,00Above median
    Cash Conv1,36Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Polyrizon Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    Net selling0 buys · 6 sellsnet -$133K4 insiders · last 365d
    • Izraeli TomerDirector, Chief Executive Officer · Ordinary SharesSold 500 @ $11,85$6K · 2026-03-31
    • Carmel LironDirector · Ordinary SharesSold 942 @ $12,36$12K · 2026-03-31
    • Adler OzDirector · Ordinary SharesSold 3 292 @ $12,05$40K · 2026-03-31
    • Carmel LironDirector · Ordinary SharesSold 100 @ $11,00$1K · 2026-03-30
    • Izraeli TomerDirector, Chief Executive Officer · Ordinary SharesSold 3 900 @ $10,90$43K · 2026-03-30
    • Turgeman TidharDirector, Chief Technology Officer · Ordinary SharesSold 2 917 @ $10,90$32K · 2026-03-30

    Short positioning

    49.8Kshares short+23.0% vs prior
    1days to cover
    65.6%short of daily vol
    2.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PLRZ.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): -15.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): -15.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 29.03xDerived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 299.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -380.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -294.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -99.4%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -115.9%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2022-12-31): 133.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -99.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 286.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -48.9%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 297.2%Derived (calculated)
    • Capex (annual): USD 7KSEC XBRL filing
    • Current liabilities (annual): USD 443KSEC XBRL filing
    • Cash & equivalents (annual): USD 1.31MSEC XBRL filing
    • Total assets (annual): USD 21.44MSEC XBRL filing
    • Operating cash flow (annual): USD -4.53MSEC XBRL filing
    • Net income (annual): USD -3.33MSEC XBRL filing
    • Shares outstanding (annual): 1.61MSEC XBRL filing
    • Shareholders' equity (annual): USD 20.99MSEC XBRL filing
    • Current assets (annual): USD 12.86MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES 5SEC XBRL filing
    • R&D expense (annual): USD 2.13MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-01 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-01 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-07-01EVENTQ3 2026 earnings (expected) estimated date
    2026-06-24 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-06-24EVENTQ2 2026 earnings (expected) estimated date
    2026-03-31 00:00 UTCINSIDER6 insider transactions — 2026-03 · net sell $133k
    2026-03-31INSIDERIzraeli Tomer sold 500 sh Ordinary Shares — Director, Chief Executive Officer ~$6k
    2026-03-31INSIDERCarmel Liron sold 942 sh Ordinary Shares — Director ~$12k
    2026-03-31INSIDERAdler Oz sold 3.3k sh Ordinary Shares — Director ~$40k
    2026-03-30INSIDERCarmel Liron sold 100 sh Ordinary Shares — Director ~$1k
    2026-03-30INSIDERIzraeli Tomer sold 3.9k sh Ordinary Shares — Director, Chief Executive Officer ~$43k
    2026-03-30INSIDERTurgeman Tidhar sold 2.9k sh Ordinary Shares — Director, Chief Technology Officer ~$32k
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage